Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XFOR
SellSinkerX4 Pharmaceuticals, Inc. · Healthcare · United States · $401M · Avg Vol: $3M/d
COMPANY DESCRIPTION
X4 Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing novel therapies for rare diseases, primarily those characterized by immune system dysfunction, utilizing its proprietary CXCR4 antagonist platform. The company's competitive edge is built on targeting high unmet medical needs in orphan disease populations, which can provide regulatory advantages and market exclusivity. X4 is a niche player focused on advancing precision medicines like its lead candidate, mavorixafor.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 2.6M | 35.1M | 1273.2% | 15.8M | 16.0M | -54.5% |
| EPS | -119.70 | -1.96 | -1.01 | -0.34 | -1.87 | — | 1.43 | — | — |
| Shares | — | 94.3M | 94.3M | 94.3M | 90.9M | -3.6% | 99.1M | — | — |
| Debt | — | 38.4M | 58.3M | 78.1M | 77.3M | 26.2% | 77.2M | — | — |
| Equity | — | 74.1M | 51.1M | 22.1M | 186.3M | 36.0% | — | — | — |
| Op CF | — | -77.1M | -96.5M | -130.9M | -85.6M | — | -83.7M | — | — |
| Inv CF | — | -0.1M | -14.9M | 67.0M | 8.2M | — | — | — | — |
| Fin CF | — | 117.2M | 88.5M | 20.3M | 238.6M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XFOR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc.(you) | $401M | 26 | Sell |
| PRTC.L | PureTech Health plc | $415M | 27 | Sell |
| PRLD | Prelude Therapeutics Incorporated | $437M | 25 | Sell |
| ARCT | Arcturus Therapeutics Holdings Inc. | $432M | 25 | Sell |
| BNTC | Benitec Biopharma Inc. | $428M | 23 | Sell |
| CCCC | C4 Therapeutics, Inc. | $474M | 27 | Sell |
| SABS | SAB Biotherapeutics, Inc. | $345M | 23 | Sell |
| PALI | Palisade Bio, Inc. | $349M | 29 | Sell |
| RZLT | Rezolute, Inc. | $445M | 21 | Sell |
| RLMD | Relmada Therapeutics, Inc. | $462M | 20 | Sell |
Peer medians: ROE -30.2% · P/E 27.1x · Gross margin 58.1%